**STANDARD COMMERCIAL DRUG FORMULARY**
**PRIOR AUTHORIZATION GUIDELINES**

**AVACOPAN**

| Generic | Brand | HICL | GCN | Medi-Span | Exception/Other |
|---|---|---|---|---|---|
| AVACOPAN | TAVNEOS | 47626 | | GPI-10 (8580551000) | |

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] or microscopic polyangiitis [MPA]) and meet **ALL** of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a rheumatologist or nephrologist
   - The patient is ANCA seropositive (anti-PR3 or anti-MPO)
   - Tavneos will be used as adjunctive therapy in combination with standard therapy including glucocorticoids (e.g., methylprednisolone, prednisone)

   If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #6 per day.**
   If no, do not approve.
   **INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

   Our guideline named **AVACOPAN (Tavneos)** requires the following rule(s) be met for approval:
   A. You have severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (inflammation of blood vessels) (granulomatosis with polyangiitis [GPA: condition that affects the blood vessels] or microscopic polyangiitis [MPA: condition that affects the blood vessels])
   B. You are 18 years of age or older
   C. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or nephrologist (a type of kidney doctor)
   D. You are ANCA seropositive for anti-PR3 or anti-MPO (a type of lab test)
   E. Tavneos will be used as adjunctive (add-on) therapy in combination with standard therapy including glucocorticoids (such as methylprednisolone, prednisone)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**

# AVACOPAN

## GUIDELINES FOR USE (CONTINUED)

## RENEWAL CRITERIA

1. Does the patient have a diagnosis of severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] or microscopic polyangiitis [MPA]) AND meet the following criterion?
   - The patient continues to benefit from therapy (e.g., improvement of clinical manifestations, if renal vasculitis - improvement in eGFR and proteinuria values, reduction of corticosteroid dose without disease flares)

   If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #6 per day.**
   If no, do not approve.
   **RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

   Our guideline named **AVACOPAN (Tavneos)** requires the following rule(s) be met for renewal:
   A. You have severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (inflammation of blood vessels) (granulomatosis with polyangiitis [GPA: condition that affects the blood vessels] or microscopic polyangiitis [MPA: condition that affects the blood vessels])
   B. You continue to benefit from the medication

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

## RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Tavneos.

## REFERENCES

- Tavneos [Prescribing Information]. Cincinnati, OH: ChemoCentryx Inc.; October 2021.

| Library | Commercial | NSA |
|---|---|---|
| Yes | Yes | No |

Part D Effective: N/A
Commercial Effective: 10/24/22
Created: 02/22
Client Approval: 10/22
P&T Approval: 01/22